The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity.
暂无分享,去创建一个
S. Iida | A. Wakita | R. Ueda | H. Komatsu | T. Ishida | S. Kusumoto | H. Yano | A. Inagaki | Jianmin Ding | M. Nitta | A. Ito | M. Ri | F. Mori
[1] K. Hristova,et al. The achondroplasia mutation does not alter the dimerization energetics of the fibroblast growth factor receptor 3 transmembrane domain. , 2006, Biochemistry.
[2] W. Vainchenker,et al. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. , 2006, Blood.
[3] K. Hristova,et al. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. , 2006, Journal of molecular biology.
[4] Michael W Parker,et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer , 2005, Nature Structural &Molecular Biology.
[5] S. Iida,et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. , 2004, Blood.
[6] S. Constantinescu,et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. , 2003, Molecular cell.
[7] E. Mekada,et al. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. , 2002, Molecular biology of the cell.
[8] K. Kaushansky,et al. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production , 2002, Oncogene.
[9] C. Deber,et al. Interhelical hydrogen bonds in the CFTR membrane domain , 2001, Nature Structural Biology.
[10] H. Lodish,et al. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[11] W. DeGrado,et al. Polar side chains drive the association of model transmembrane peptides. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[12] William F. DeGrado,et al. Asparagine-mediated self-association of a model transmembrane helix , 2000, Nature Structural Biology.
[13] V. Broudy,et al. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. , 1999, Blood.
[14] I. Wilson,et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. , 1999, Science.
[15] I. Wilson,et al. Erythropoietin receptor activation by a ligand-induced conformation change. , 1999, Science.
[16] K. Kaushansky,et al. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[17] R. D'Andrea,et al. Activating mutations in cytokine receptors: implications for receptor function and role in disease. , 1997, Blood.
[18] W. Reardon,et al. A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans. , 1996, Journal of medical genetics.
[19] G. Nolan,et al. Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer. , 1996, Blood.
[20] B. Bormann,et al. Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor , 1996, Nature Structural Biology.
[21] W. Alexander,et al. Point mutations within a dimer interface homology domain of c‐Mpl induce constitutive receptor activity and tumorigenicity. , 1995, The EMBO journal.
[22] H. Kitayama,et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. , 1995, Blood.
[23] J. Mornon,et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[24] H. Lodish,et al. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity , 1990, Nature.
[25] W. Reardon,et al. Spectrum of Craniosynostosis Phenotypes Associated with Novel Mutations at the Fibroblast Growth Factor Receptor 2 Locus , 1996, European journal of human genetics : EJHG.